Cediranib , ≥98% , 288383-20-0

CAS NO.：288383-20-0

Empirical Formula: C25H27FN4O3

Molecular Weight: 450.51

MDL number: MFCD09954115

EINECS: 670-946-2

PRODUCT Properties

• Melting point: 135-138°C
• Boiling point: 626.6±55.0 °C(Predicted)
• Density: 1.285
• storage temp.: Sealed in dry,Store in freezer, under -20°C
• solubility: Acetone (Slightly), DMSO (Slightly), Methanol (Slightly)
• form: Solid
• pka: 16.14±0.30(Predicted)
• color: White to Off-White
• InChI: InChI=1S/C25H27FN4O3/c1-16-12-17-19(29-16)6-7-21(24(17)26)33-25-18-13-22(31-2)23(14-20(18)27-15-28-25)32-11-5-10-30-8-3-4-9-30/h6-7,12-15,29H,3-5,8-11H2,1-2H3
• InChIKey: XXJWYDDUDKYVKI-UHFFFAOYSA-N
• SMILES: N1=C2C(C=C(OC)C(OCCCN3CCCC3)=C2)=C(OC2C=CC3=C(C=2F)C=C(C)N3)N=C1

Description and Uses

Receptors for VEGF have central roles in vasculogenesis and angiogenesis and thus serve as targets for cancer therapy. Cediranib is a potent inhibitor of VEGF receptor tyrosine kinases, including VEGFR1, 2, and 3 (IC₅₀s = 5, 1, and 3 nM, respectively). It also potently inhibits a variety of other receptor and non-receptor tyrosine kinases, including several in the platelet-derived growth factor, fibroblast growth factor, and endothelial growth factor receptor families. Cediranib blocks tubule formation by human umbilical vein endothelial cells in vitro and prevents angiogenesis as well as xenograft tumor growth in vivo. Because of these effects, cediranib has potential use in a range of cancers.

Cediranib is a drug for blocking angiogenesis, study on cervical cancer molecular targeted drug and clinical application progress, value of correlative biomakers in the understanding of tumor biology.

Safety

• Symbol(GHS): GHS07
• Signal word: Warning
• Hazard statements: H302-H315-H319-H335
• Precautionary statements: P261-P305+P351+P338
• HS Code: 2933599590